Adherence to Pre-Exposure Prophylaxis for HIV Prevention in a Clinical Setting

被引:63
|
作者
Montgomery, Madeline C. [1 ]
Oldenburg, Catherine E. [2 ]
Nunn, Amy S. [3 ]
Mena, Leandro [4 ]
Anderson, Peter [5 ]
Liegler, Teri [6 ]
Mayer, Kenneth H. [7 ,8 ,9 ]
Patel, Rupa [10 ]
Almonte, Alexi [1 ]
Chan, Philip A. [1 ]
机构
[1] Brown Univ, Div Infect Dis, Providence, RI 02912 USA
[2] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
[3] Brown Univ, Sch Publ Hlth, Dept Behav & Social Sci, Providence, RI 02912 USA
[4] Univ Mississippi, Div Infect Dis, Jackson, MS 39216 USA
[5] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Aurora, CO USA
[6] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[7] Fenway Hlth, Fenway Inst, Boston, MA USA
[8] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA USA
[9] Harvard Univ, Sch Med, Boston, MA USA
[10] Washington Univ, Div Infect Dis, St Louis, MO USA
来源
PLOS ONE | 2016年 / 11卷 / 06期
关键词
DRUG-RESISTANCE; MEN; INFECTION;
D O I
10.1371/journal.pone.0157742
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background The HIV epidemic in the United States (US) disproportionately affects gay, bisexual, and other men who have sex with men (MSM). Pre-exposure prophylaxis (PrEP) using co-formulated tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) has demonstrated high efficacy in reducing HIV incidence among MSM. However, low adherence was reported in major efficacy trials and may present a substantial barrier to successful PrEP implementation. Rates of adherence to PrEP in "real-world" clinical settings in the US remain largely unknown. Methods We reviewed demographic and clinical data for the first 50 patients to enroll in a clinical PrEP program in Providence, Rhode Island. We analyzed self-reported drug adherence as well as drug concentrations in dried blood spots (DBS) from patients who attended either a three-or six-month follow-up appointment. We further assessed drug concentrations and the resistance profile of a single patient who seroconverted while taking PrEP. Results Of the first 50 patients to be prescribed PrEP, 62% attended a follow-up appointment at three months and 38% at six months. Of those who attended an appointment at either time point (70%, n = 35), 92% and 95% reported taking +/- 4 doses/week at three and six months, respectively. Drug concentrations were performed on a random sample of 20 of the 35 patients who attended a follow-up appointment. TDF levels consistent with +/- 4 doses/week were found in 90% of these patients. There was a significant correlation between self-reported adherence and drug concentrations (r = 0.49, p = 0.02). One patient who had been prescribed PrEP seroconverted at his three-month follow-up visit. The patient's drug concentrations were consistent with daily dosing. Population sequencing and ultrasensitive allele-specific PCR detected the M184V mutation, but no other TDF- or FTC-associated mutations, including those present as minor variants. Conclusion In this clinical PrEP program, adherence was high, and self-reported drug adherence accurately reflected drug concentrations as measured by DBS.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] PRE-EXPOSURE PROPHYLAXIS FOR HIV PREVENTION
    Cremin, I.
    Hallett, T.
    Dybul, M.
    Piot, P.
    Garnett, G.
    [J]. SEXUALLY TRANSMITTED INFECTIONS, 2011, 87 : A36 - A36
  • [2] Pre-exposure prophylaxis as HIV prevention in the UK
    Brady, Michael
    [J]. THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2016, 7 (03) : 150 - 152
  • [3] HIV prevention using pre-exposure prophylaxis
    Daou, S.
    Calmy, A.
    [J]. REVUE DE MEDECINE INTERNE, 2011, 32 (11): : 658 - 662
  • [4] Oral pre-exposure prophylaxis for HIV prevention
    Garcia-Lerma, J. Gerardo
    Paxton, Lynn
    Kilmarx, Peter H.
    Heneine, Walid
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2010, 31 (02) : 74 - 81
  • [5] PrEP: pre-exposure prophylaxis for HIV prevention
    Page, Matthew
    Nicholls, Jane
    [J]. TRENDS IN UROLOGY & MENS HEALTH, 2018, 9 (04) : 22 - 24
  • [6] Pre-exposure prophylaxis for prevention of HIV infection
    Lee, Joseph Wei En
    Lim, Sze Wern
    Choy, Chiaw Yee
    Wong, Chen Seong
    [J]. SINGAPORE MEDICAL JOURNAL, 2023, 64 (10) : 624 - 628
  • [7] Individualized Adherence Benchmarks for HIV Pre-Exposure Prophylaxis
    Ibrahim, Mustafa E.
    Castillo-Mancilla, Jose R.
    Yager, Jenna
    Brooks, Kristina M.
    Bushman, Lane
    Saba, Laura
    Kiser, Jennifer J.
    MaWhinney, Samantha
    Anderson, Peter L.
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2021, 37 (06) : 421 - 428
  • [8] Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm
    Haberer, Jessica E.
    Bangsberg, David R.
    Baeten, Jared M.
    Curran, Kathryn
    Koechlin, Florence
    Amico, K. Rivet
    Anderson, Peter
    Mugo, Nelly
    Venter, Francois
    Goicochea, Pedro
    Caceres, Carlos
    O'Reilly, Kevin
    [J]. AIDS, 2015, 29 (11) : 1277 - 1285
  • [9] Rethinking HIV pre-exposure prophylaxis prevention strategy
    Kistan, Jesne
    Serwadda, David
    [J]. LANCET HIV, 2016, 3 (04): : E155 - E157
  • [10] What is the Place of Pre-Exposure Prophylaxis in HIV Prevention?
    De Man, Jeroen
    Colebunders, Robert
    Florence, Eric
    Laga, Marie
    Kenyon, Christopher
    [J]. AIDS REVIEWS, 2013, 15 (02) : 102 - 111